CREG1

Summary

CREG1 (cellular repressor of E1A stimulated genes 1, HGNC:2351) is a protein-coding gene on chromosome 1q24.2, encoding Protein CREG1 (O75629). May contribute to the transcriptional control of cell growth and differentiation.

The adenovirus E1A protein both activates and represses gene expression to promote cellular proliferation and inhibit differentiation. The protein encoded by this gene antagonizes transcriptional activation and cellular transformation by E1A. This protein shares limited sequence similarity with E1A and binds both the general transcription factor TBP and the tumor suppressor pRb in vitro. This gene may contribute to the transcriptional control of cell growth and differentiation.

Source: NCBI Gene 8804 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 45 total
• MANE Select transcript: NM_003851

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2351
Approved symbol	CREG1
Name	cellular repressor of E1A stimulated genes 1
Location	1q24.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000143162
Ensembl biotype	protein_coding
OMIM	618055
Entrez	8804

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000370509, ENST00000466652, ENST00000856000, ENST00000856001, ENST00000856002

RefSeq mRNA: 1 — MANE Select: NM_003851 NM_003851

CCDS: CCDS1262

Canonical transcript exons

ENST00000370509 — 4 exons

Exon	Start	End
ENSE00000958440	167548002	167548121
ENSE00000958441	167546101	167546285
ENSE00001445787	167541013	167542301
ENSE00001452907	167553388	167553762

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 99.54.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 103.2142 / max 2680.9930, expressed in 1819 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
15787	99.0080	1819
15788	4.1981	1494
15786	0.0081	3

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper leg skin	UBERON:0004262	99.54	gold quality
hair follicle	UBERON:0002073	99.41	gold quality
mammalian vulva	UBERON:0000997	99.02	gold quality
upper arm skin	UBERON:0004263	98.86	gold quality
gall bladder	UBERON:0002110	98.64	gold quality
parotid gland	UBERON:0001831	98.60	gold quality
lower lobe of lung	UBERON:0008949	98.55	gold quality
skin of hip	UBERON:0001554	98.50	gold quality
gingival epithelium	UBERON:0001949	98.46	gold quality
gingiva	UBERON:0001828	98.42	gold quality
penis	UBERON:0000989	98.38	gold quality
trabecular bone tissue	UBERON:0002483	98.38	gold quality
right coronary artery	UBERON:0001625	98.25	gold quality
right adrenal gland cortex	UBERON:0035827	98.25	gold quality
mammary duct	UBERON:0001765	98.23	gold quality
superficial temporal artery	UBERON:0001614	98.17	gold quality
monocyte	CL:0000576	98.14	gold quality
corpus epididymis	UBERON:0004359	98.10	gold quality
right adrenal gland	UBERON:0001233	98.08	gold quality
mononuclear cell	CL:0000842	98.06	gold quality
left adrenal gland	UBERON:0001234	98.03	gold quality
synovial joint	UBERON:0002217	98.03	gold quality
epithelium of mammary gland	UBERON:0003244	98.01	gold quality
adrenal cortex	UBERON:0001235	97.91	gold quality
leukocyte	CL:0000738	97.87	gold quality
left adrenal gland cortex	UBERON:0035825	97.87	gold quality
mucosa of stomach	UBERON:0001199	97.84	gold quality
decidua	UBERON:0002450	97.82	gold quality
descending thoracic aorta	UBERON:0002345	97.78	gold quality
left coronary artery	UBERON:0001626	97.76	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 11.

Experiment	Marker?	Max mean expression
E-MTAB-7407	yes	1247.40
E-MTAB-6701	yes	51.48
E-CURD-122	yes	47.49
E-HCAD-10	yes	41.54
E-MTAB-6678	yes	41.13
E-MTAB-10553	yes	28.22
E-CURD-112	yes	21.36
E-HCAD-13	yes	20.62
E-HCAD-9	yes	20.52
E-MTAB-9388	yes	6.26
E-ENAD-17	no	42.10
E-CURD-114	no	19.81
E-MTAB-5061	no	3.80
E-MTAB-9467	no	0.79
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
HSPA4	Repression

Upstream regulators (CollecTRI, top): E2F4

miRNA regulators (miRDB)

87 targeting CREG1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-3663-3P	99.84	70.39	798
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-2052	99.79	69.37	2031

Literature-anchored findings (GeneRIF, showing 21)

• putative flavin mononucleotide-binding pocket in CREG is sterically blocked by a loop and several key bulky residues (PMID:16344469)
• CREG promotes a mature smooth muscle cell phenotype and reduces neointimal formation in balloon-injured rat carotid artery. (PMID:18267954)
• We demonstrate that CREG is expressed in the vascular endothelium; data suggests that CREG differentially regulates the growth of the denuded artery wall and smooth vascular muscle cell. (PMID:18472385)
• The expression of CREG improves cardiac functions and inhibits cardiac hypertrophy, inflammation and fibrosis through blocking MEK-ERK1/2-dependent signalling. (PMID:19413895)
• CREG plays a critical role in the inhibition of SMC migration, as well as maintaining SMCs in a mature phenotype (PMID:19769965)
• CREG plays a key role in modulating VSMC apoptosis through the p38 and JNK signal transduction pathways, both in vitro and in s (PMID:20060003)
• no ssociation between common variants of CREG and coronary artery disease in the northern Chinese Han population (PMID:20951690)
• Data suggest that soluble CREG protein can exert its biological function via glycosylation-independent binding to the extracellular domains 11-13 of cell surface M6P/IGF2R, modulating SMC phenotypic switching from contractile to proliferative. (PMID:21195083)
• Cooperation of CREG1 and p16 (INK4a) inhibits the expression of cyclin A and cyclin B by inhibiting promoter activity thereby decreasing mRNA and protein levels; these proteins are required for S-phase entry and G2/M transition. (PMID:21263217)
• CREG plays a critical role in protecting the vascular endothelium from apoptosis, and the protective effort of CREG against ECs apoptosis is through the activation of the VEGF/PI3K/AKT signaling pathway (PMID:21872252)
• Upregulation of CREG expression induced HUVEC migration. (PMID:21939655)
• Suggest that CREG is a novel adventitial fibroblast phenotypic modulator in a p38MAPK-dependent manner. (PMID:23040447)
• miR-31 not only directly binds to its target gene CREG and modulates the vascular smooth muscle cells(VSMC) phenotype through this interaction, but also can be an important biomarker in diseases involving VSMC phenotypic modulation. (PMID:23518389)
• CREG can inhibit NF-kappaB activation, TNF-alpha-induced inflammatory responses and the hyperpermeability of endothelial cells. (PMID:23580165)
• The results suggest a novel role of CREG to promote HUVEC proliferation through the ERK/cyclin E signaling pathway. (PMID:24018888)
• Results indicate that cellular repressor of E1A-stimulated gene 1 protein (CREG1) increases endothelial cell (EC) filopodia formation. (PMID:24896341)
• These results indicate that CREG1 is a down-stream effector of KRAS in a sub-type of non-small cell lung cancer cells and a novel candidate biomarker or therapeutic target for KRAS mutant non-small cell lung cancer. (PMID:26722374)
• Studies demonstrated that CREG may modulate homeostasis of vascular wall cells and inhibit inflammation of vascular tissue cells and macrophages. Mechanistically, CREG behaves like a typical soluble lysosomal protein that regulates the formation and maturation of lysosomes by modulating the small GTPase protein Rab7, to mediate autophagy in vascular vascular tissue cells. [review] (PMID:27784214)
• DNA hypermethylation: A novel mechanism of CREG gene suppression and atherosclerogenic endothelial dysfunction. (PMID:32067910)
• The role of CREG1 in megakaryocyte maturation and thrombocytopoiesis. (PMID:37496998)
• CREG1 deficiency impaired myoblast differentiation and skeletal muscle regeneration. (PMID:38272853)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
		ENSDARG00000105154
mus_musculus	Creg1	ENSMUSG00000040713
rattus_norvegicus	Creg1	ENSRNOG00000003291
drosophila_melanogaster	CREG	FBGN0025456

Paralogs (1): CREG2 (ENSG00000175874)

Protein

Protein identifiers

Protein CREG1 — O75629 (reviewed: O75629)

Alternative names: Cellular repressor of E1A-stimulated genes 1

All UniProt accessions (2): O75629, A0A3B3IRL2

UniProt curated annotations — full annotation on UniProt →

Function. May contribute to the transcriptional control of cell growth and differentiation. Antagonizes transcriptional activation and cellular transformation by the adenovirus E1A protein. The transcriptional control activity of cell growth requires interaction with IGF2R.

Subunit / interactions. Homodimer. Interacts with IGF2R; the interaction is dependent on glycosylation.

Subcellular location. Secreted.

Post-translational modifications. N-glycosylated.

Similarity. Belongs to the CREG family.

RefSeq proteins (1): NP_003842* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR012349	Split_barrel_FMN-bd	Homologous_superfamily
IPR014631	CREG	Family
IPR055343	CREG_beta-barrel	Domain

Pfam: PF13883

UniProt features (23 total): helix 10, strand 7, glycosylation site 3, signal peptide 1, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1XHN	X-RAY DIFFRACTION	1.95

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75629-F1	88.08	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (3): 160, 193, 216

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation

MSigDB gene sets: 278 (showing top): MULLIGHAN_NPM1_SIGNATURE_3_UP, REACTOME_INNATE_IMMUNE_SYSTEM, MODULE_169, GOBP_VACUOLE_ORGANIZATION, GOCC_SECRETORY_GRANULE, AAGCCAT_MIR135A_MIR135B, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, GOBP_VESICLE_MEDIATED_TRANSPORT, MODULE_16, SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_DN, MODULE_75, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, GOMF_INSULIN_LIKE_GROWTH_FACTOR_RECEPTOR_BINDING, GOBP_VACUOLAR_ACIDIFICATION, RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN

GO Biological Process (7): regulation of transcription by RNA polymerase II (GO:0006357), endocytosis (GO:0006897), autophagy (GO:0006914), lysosome organization (GO:0007040), lysosomal lumen acidification (GO:0007042), regulation of DNA-templated transcription (GO:0006355), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (2): transcription corepressor activity (GO:0003714), insulin-like growth factor receptor binding (GO:0005159)

GO Cellular Component (9): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), transcription regulator complex (GO:0005667), lysosome (GO:0005764), endosome (GO:0005768), azurophil granule lumen (GO:0035578), extracellular exosome (GO:0070062), cytoplasm (GO:0005737), endomembrane system (GO:0012505)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
regulation of DNA-templated transcription	2
DNA-templated transcription	2
transcription by RNA polymerase II	1
vesicle budding from membrane	1
membrane invagination	1
vesicle-mediated transport	1
import into cell	1
catabolic process	1
transmembrane transport	1
process utilizing autophagic mechanism	1
lytic vacuole organization	1
vacuolar acidification	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
negative regulation of RNA biosynthetic process	1
transcription coregulator activity	1
negative regulation of DNA-templated transcription	1
signaling receptor binding	1
protein-containing complex	1
lytic vacuole	1
endomembrane system	1
cytoplasmic vesicle	1
vacuolar lumen	1
secretory granule lumen	1
azurophil granule	1
extracellular vesicle	1
intracellular anatomical structure	1
vacuole	1
plasma membrane	1

Protein interactions and networks

STRING

658 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CREG1	IGF2R	P11717	611
CREG1	M6PR	P20645	542
CREG1	CASP3	P42574	478
CREG1	HLA-B	P01889	446
CREG1	FTL	P02792	442
CREG1	EXOC4	Q96A65	434
CREG1	TBP	P20226	420
CREG1	MEGF6	O75095	410
CREG1	A0A2R8YDH4	A0A2R8YDH4	400
CREG1	EPDR1	Q9UM22	398
CREG1	IFI30	P13284	395
CREG1	TSKU	Q8WUA8	383
CREG1	CD46	P15529	375
CREG1	MPZL2	O60487	373
CREG1	PIR	O00625	373

IntAct

29 interactions, top by confidence:

A	B	Type	Score
KBTBD7	METTL15	psi-mi:“MI:0914”(association)	0.730
AIRE	ALOX12B	psi-mi:“MI:0914”(association)	0.530
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
Prdm16	ESYT2	psi-mi:“MI:0914”(association)	0.350
ZBED1		psi-mi:“MI:0914”(association)	0.350
P		psi-mi:“MI:0914”(association)	0.350
rep	ZNF609	psi-mi:“MI:0914”(association)	0.350
ST7	A2ML1	psi-mi:“MI:0914”(association)	0.350
PTDSS1	IGLL5	psi-mi:“MI:0914”(association)	0.350
IGF2R	MANBA	psi-mi:“MI:0914”(association)	0.350
ZBED1	SPAG9	psi-mi:“MI:0914”(association)	0.350
CREG1	HNRNPA1L2	psi-mi:“MI:0914”(association)	0.350
MRM1	RIMOC1	psi-mi:“MI:0914”(association)	0.350
SH2D3A	A2ML1	psi-mi:“MI:0914”(association)	0.350
PCP4	A2ML1	psi-mi:“MI:0914”(association)	0.350
HSPA8	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
RPL7L1	A2ML1	psi-mi:“MI:0914”(association)	0.350
TCEAL9	TGM5	psi-mi:“MI:0914”(association)	0.350
THY1	CREG1	psi-mi:“MI:0914”(association)	0.350
INSR	RIMOC1	psi-mi:“MI:0914”(association)	0.350
	ARHGAP32	psi-mi:“MI:2364”(proximity)	0.270
glyA	CREG1	psi-mi:“MI:0915”(physical association)	0.000
purT	CREG1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (33): CREG1 (Synthetic Lethality), CREG1 (Affinity Capture-MS), CREG1 (Affinity Capture-MS), CREG1 (Affinity Capture-MS), CREG1 (Affinity Capture-MS), CREG1 (Reconstituted Complex), DLD (Co-fractionation), GRHPR (Co-fractionation), PMPCA (Co-fractionation), TPI1 (Co-fractionation), CREG1 (Co-fractionation), CREG1 (Affinity Capture-MS), TBP (Reconstituted Complex), RB1 (Reconstituted Complex), RBL1 (Reconstituted Complex)

ESM2 similar proteins: A0JJZ6, G1T7U7, H0VCJ6, O08841, O35448, O70489, O75629, O88668, P09531, P13284, P68827, Q02083, Q0J6H8, Q0P5H1, Q10S70, Q1JQA0, Q3SZL5, Q5M872, Q5VSG8, Q5XI31, Q5ZJ73, Q5ZMM1, Q65XS5, Q67WE2, Q69ZQ1, Q6NSJ0, Q6P1J0, Q6PD26, Q6W3E9, Q6W3F0, Q6YX89, Q6ZIF9, Q75UG4, Q7X6J9, Q7Z4N8, Q84TW8, Q8BGC9, Q8BJ48, Q8BMS2, Q8C255

Diamond homologs: O75629, O88668, Q5ZJ73, Q8BGC9, Q8IUH2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

45 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

404 predictions. Top by Δscore:

Variant	Effect	Δscore
1:167546099:A:AC	donor_gain	1.0000
1:167546100:C:CT	donor_gain	1.0000
1:167546100:CTGA:C	donor_gain	1.0000
1:167546100:CTGAA:C	donor_gain	1.0000
1:167547997:CTTA:C	donor_loss	1.0000
1:167547998:TTACC:T	donor_loss	1.0000
1:167547999:TA:T	donor_loss	1.0000
1:167548000:A:C	donor_loss	1.0000
1:167548000:AC:A	donor_gain	1.0000
1:167548001:C:G	donor_loss	1.0000
1:167548001:CC:C	donor_gain	1.0000
1:167548117:TTCTC:T	acceptor_gain	1.0000
1:167548119:CTC:C	acceptor_gain	1.0000
1:167548122:C:CC	acceptor_gain	1.0000
1:167548122:CT:C	acceptor_loss	1.0000
1:167548123:T:C	acceptor_loss	1.0000
1:167553382:GCTCA:G	donor_loss	1.0000
1:167553383:CTCAC:C	donor_loss	1.0000
1:167553384:TCACC:T	donor_loss	1.0000
1:167553386:A:AG	donor_loss	1.0000
1:167553387:C:CG	donor_loss	1.0000
1:167544342:A:C	acceptor_gain	0.9900
1:167546093:GTAC:G	donor_loss	0.9900
1:167546094:TAC:T	donor_loss	0.9900
1:167546095:ACTT:A	donor_loss	0.9900
1:167546096:C:G	donor_loss	0.9900
1:167546096:CTTA:C	donor_gain	0.9900
1:167546097:T:TC	donor_loss	0.9900
1:167546098:T:TC	donor_loss	0.9900
1:167546099:A:T	donor_loss	0.9900

AlphaMissense

1409 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:167553418:G:C	S108R	0.990
1:167553418:G:T	S108R	0.990
1:167553420:T:G	S108R	0.990
1:167548072:C:G	C135S	0.988
1:167548073:A:T	C135S	0.988
1:167548072:C:T	C135Y	0.987
1:167553566:G:T	A59D	0.987
1:167546119:T:C	Y214C	0.986
1:167548036:C:G	C147S	0.986
1:167548036:C:T	C147Y	0.986
1:167548037:A:G	C147R	0.986
1:167548037:A:T	C147S	0.986
1:167548035:A:C	C147W	0.985
1:167548102:A:G	L125P	0.985
1:167546217:C:A	W181C	0.984
1:167546217:C:G	W181C	0.984
1:167553466:G:C	S92R	0.984
1:167553466:G:T	S92R	0.984
1:167553468:T:G	S92R	0.984
1:167553537:C:G	G69R	0.984
1:167546119:T:G	Y214S	0.983
1:167546120:A:G	Y214H	0.983
1:167548015:C:T	G154E	0.983
1:167546237:G:C	H175D	0.982
1:167548071:G:C	C135W	0.982
1:167546151:A:C	F203L	0.980
1:167546151:A:T	F203L	0.980
1:167546153:A:G	F203L	0.980
1:167546201:A:G	W187R	0.980
1:167546201:A:T	W187R	0.980

dbSNP variants (sampled 300 via entrez): RS1000227556 (1:167541948 C>T), RS1000377383 (1:167550937 A>C), RS1000587843 (1:167540515 T>C), RS1000674168 (1:167549067 C>A), RS1000695313 (1:167546839 T>C), RS1000738647 (1:167548403 A>G), RS1000748328 (1:167550683 G>A), RS1000784733 (1:167553151 G>A), RS1000853424 (1:167552765 G>C,T), RS1001116064 (1:167549434 G>A), RS1001326375 (1:167544087 A>G), RS1001344136 (1:167549758 C>T), RS1001365205 (1:167544340 A>G), RS1001550817 (1:167555445 C>G), RS1001576168 (1:167550140 C>T)

Disease associations

OMIM: gene MIM:618055 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006585_503	Blood protein levels	5.000000e-28
GCST009798_40	Asthma	8.000000e-11

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	8
Tretinoin	increases expression	3
bisphenol A	increases expression, affects expression	2
mercuric bromide	increases expression, affects cotreatment	2
Arsenic	increases abundance, increases expression, increases response to substance, affects cotreatment	2
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
Doxorubicin	affects response to substance, decreases expression	2
Estradiol	affects cotreatment, increases expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Smoke	decreases expression	2
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
sulforaphane	increases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
cadmium acetate	decreases expression	1
dibenzo(a,l)pyrene	decreases expression	1
tamibarotene	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
fenpyroximate	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
thifluzamide	increases expression	1
abrine	decreases expression	1
dorsomorphin	increases expression, affects cotreatment	1
Temozolomide	decreases expression	1
Vorinostat	increases expression	1
Ethanol	increases expression, affects cotreatment, increases abundance	1
Antimycin A	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.